CA3216031A1 — Capsid inhibitors for the treatment of hiv
Assigned to Gilead Sciences Inc · Expires 2020-01-23 · 6y expired
What this patent protects
The present disclosure relates to compounds of Formula (la) and (lb) or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
USPTO Abstract
The present disclosure relates to compounds of Formula (la) and (lb) or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.